These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8071848)

  • 1. Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect.
    Thijssen HH; Janssen YP
    J Pharmacol Exp Ther; 1994 Aug; 270(2):554-8. PubMed ID: 8071848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat.
    Mosterd JJ; Thijssen HH
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1081-5. PubMed ID: 1545379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase.
    Thijssen HH; Baars LG
    Biochem Pharmacol; 1989 Apr; 38(7):1115-20. PubMed ID: 2706010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat.
    Fasco MJ; Principe LM
    J Biol Chem; 1982 May; 257(9):4894-901. PubMed ID: 7068669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat.
    de Boer-van den Berg MA; Thijssen HH; Vermeer C
    Biochim Biophys Acta; 1986 Oct; 884(1):150-7. PubMed ID: 3490277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.
    Yamanaka Y; Yamano M; Yasunaga K; Shike T; Uchida K
    Thromb Res; 1990 Jan; 57(2):205-14. PubMed ID: 2315885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats.
    MacNicoll AD
    Biochim Biophys Acta; 1985 May; 840(1):13-20. PubMed ID: 3995080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Puerarin offsets the anticoagulation effect of warfarin in rats by inducing rCyps, upregulating vitamin K epoxide reductase and inhibiting thrombomodulin.
    Ge B; Zhang Z; Lam TT; Zuo Z
    Biopharm Drug Dispos; 2017 Jan; 38(1):33-49. PubMed ID: 27925234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver.
    Begent LA; Hill AP; Steventon GB; Hutt AJ; Pallister CJ; Cowell DC
    J Pharm Pharmacol; 2001 Apr; 53(4):481-6. PubMed ID: 11341364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase.
    Thijssen HH; Baars LG
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1082-8. PubMed ID: 3694526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that warfarin anticoagulant action involves two distinct reductase activities.
    Fasco MJ; Hildebrandt EF; Suttie JW
    J Biol Chem; 1982 Oct; 257(19):11210-2. PubMed ID: 6811577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat.
    Thijssen HH; Janssen CA; Drittij-Reijnders MJ
    Biochem Pharmacol; 1986 Oct; 35(19):3277-82. PubMed ID: 3768021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes.
    Fasco MJ; Principe LM; Walsh WA; Friedman PA
    Biochemistry; 1983 Nov; 22(24):5655-60. PubMed ID: 6652076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin.
    Thijssen HH
    Biochem Pharmacol; 1987 Sep; 36(17):2753-7. PubMed ID: 3632704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.
    Thijssen HH; Baars LG; Vervoort-Peters HT
    Br J Pharmacol; 1988 Nov; 95(3):675-82. PubMed ID: 3207986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin resistance in a Chicago strain of rats.
    Misenheimer TM; Suttie JW
    Biochem Pharmacol; 1990 Nov; 40(9):2079-84. PubMed ID: 2242035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes.
    Hildebrandt EF; Preusch PC; Patterson JL; Suttie JW
    Arch Biochem Biophys; 1984 Feb; 228(2):480-92. PubMed ID: 6696443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.
    Guenthner TM; Cai D; Wallin R
    Biochem Pharmacol; 1998 Jan; 55(2):169-75. PubMed ID: 9448739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue distribution of selective warfarin binding sites in the rat.
    Thijssen HH; Baars LG
    Biochem Pharmacol; 1991 Nov; 42(11):2181-6. PubMed ID: 1958236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents.
    Thijssen HH; Janssen YP; Vervoort LT
    Biochem J; 1994 Jan; 297 ( Pt 2)(Pt 2):277-80. PubMed ID: 8297331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.